Skip to main content

Professor David E. Griffith, MD

Professor David E. Griffith, MD

Professor of Medicine
National Jewish Health
Denver, Colorado, USA

Related Videos

Given the results of the WILLOW and ASPEN trials, and the broad FDA label for brensocatib, how do you recommend we identify those persons with documented NCFBE who represent ideal candidates for this therapeutic approach?

Given the results of the WILLOW and ASPEN trials, and the broad FDA label for brensocatib, how do you recommend we identify those persons with documented NCFBE who represent ideal candidates for this therapeutic approach?

Can you discuss the current burden of NCFBE and the significant unmet need for the healthcare system? How do we address high disease burden, increasing prevalence, and profoundly impaired quality of life in NCFBE?

Can you discuss the current burden of NCFBE and the significant unmet need for the healthcare system? How do we address high disease burden, increasing prevalence, and profoundly impaired quality of life in NCFBE?

How should clinicians monitor brensocatib once a patient has been committed to this treatment?

How should clinicians monitor brensocatib once a patient has been committed to this treatment?

Does monitoring pulmonary function help clinicians monitor the drug effects or, possibly, improve patient compliance?

Does monitoring pulmonary function help clinicians monitor the drug effects or, possibly, improve patient compliance?

How are brensocatib and other investigational drugs in the pipeline shaping/changing the multimodal treatment landscape for NCFBE? How can you educate patients in whom you are considering this novel therapy?

How are brensocatib and other investigational drugs in the pipeline shaping/changing the multimodal treatment landscape for NCFBE? How can you educate patients in whom you are considering this novel therapy?

What are the consensus- and guideline-adherent recommendations for confirming the diagnosis of NCFBE? And what risk stratification tools might apply that would be useful when considering targeting neutrophil-mediated inflammation?

What are the consensus- and guideline-adherent recommendations for confirming the diagnosis of NCFBE? And what risk stratification tools might apply that would be useful when considering targeting neutrophil-mediated inflammation?

How does the complexity and heterogeneity of NCFBE—with underlying inflammatory and infectious precipitants—affect selection of specific therapeutic agents that might be used as part of multi-modal therapy?

How does the complexity and heterogeneity of NCFBE—with underlying inflammatory and infectious precipitants—affect selection of specific therapeutic agents that might be used as part of multi-modal therapy?

We now understand that infectious triggers are architecturally destructive of bronchial tissues, potentiated by chronic and dysregulatory inflammatory processes, producing a “vicious vortex. How does this share our new treatment map for NCFBE?

We now understand that infectious triggers are architecturally destructive of bronchial tissues, potentiated by chronic and dysregulatory inflammatory processes, producing a “vicious vortex. How does this share our new treatment map for NCFBE?

Professor Griffith, could you introduce yourself and your role at National Jewish Health, share your clinical and research focus on advancing therapies for NCFBE, and outline what you plan to discuss in this iQ&A Bronchiectasis Intelligence Zone?

Professor Griffith, could you introduce yourself and your role at National Jewish Health, share your clinical and research focus on advancing therapies for NCFBE, and outline what you plan to discuss in this iQ&A Bronchiectasis Intelligence Zone?